NRF2-KEAP1 pathway is usually altered in NSCLC tumors due to gain-of-function mutations of NFE2L2 (which encodes for NRF2) or loss-of-function alterations of KEAP1 [56]. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.